15Oct 2019

STUDY OF EXPRESSION OF PTEN IN ENDOMETRIUM AT A TERTIARY CARE CENTRE

  • Assistant Professor, Department of Pathology, Adesh Institute of Medical Sciences & Research, Bathinda, Punjab, India.
  • Senior Resident, Department of Pathology, Government Medical College, Anantnag, Jammu & Kashmir, India.
  • Assistant Professor, Department of Pathology, Government Medical College, Anantnag, Jammu & Kashmir, India.
  • Senior Consultant, Department of Health, Government of Jammu & Kashmir, Anantnag, Jammu & Kashmir.
  • Assistant Professor, Department of Pathology, Adesh Institute of Medical Sciences & Research, Bathinda, Punjab, India.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: To study the expression of PTEN (Phosphatase and Tensin homologue) in normal, hyperplastic and neoplastic endometrium by immunohistochemistry in normal to neoplastic endometrial lesions including endometrial carcinoma. Materials and Methods: Formalin fixed paraffin embedded (FFPE) sections of spectrum of endometrium in hundred different cases were taken from secretory phase to endometrial carcinoma and subjected to Immunohistochemistry using PTEN. Results: Immunoreactivity was taken as positive when a brown colour was noted in the nuclei or cytoplasm with intensity of staining being graded from 0 to 3+. Also if <10% of cells were positive a score of 0 was given, if 11 % to 30% cell were positive a score of 1+ , 31% to 60 % positive, a score as 2+ and > 60% positive cells a score of 3+ was given. Statistical analysis was performed with Chi-Square test and significant differences were noted between these 3 groups (p value < 0.05). Conclusion: A decreased expression of PTEN is a marker of the earliest endometrial premalignant lesions, and therefore we in our study suggest that PTEN immunostaining can be helpful in identifying premalignant conditions that are likely to progress to carcinoma.

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics.CA Cancer J Clin 1998; 48:6-29.
  2. Ellenson L H, Pirog EC. The Female Genital Tract. In: Kumar V, Abbas AK,Aster JC, editors. Robbins & Cotran Pathological Basis of Disease. 9th Ed. Philadelphia: Saunders;2015.Pp1013.
  3. Ronnett BM, Zaino RJ, Ellenson LH, Kurman RJ. Endometrial carcinoma. In: Kurman RJ, editor. Blaustein?s pathology of the female genital tract. 5th ed. Baltimore: Springer. 2002; p.501-59.
  4. Kanamori Y, Kigawa J, Itamochi H, Shimada M, Takahashi M, Kamazawa S et al. Correlation between Loss of PTEN Expression and Akt Phosphorylation in Endometrial Carcinoma. Clin Cancer Res. 2001; 7(4):892-95.
  5. Mutter GL. PTEN, a protean tumor suppressor. Am J Pathol .2001; 158:1895-98.
  6. Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB et al. Clinical Assessment of PTEN Loss in Endometrial Carcinoma: Immunohistochemistry Out-Performs Gene Sequencing. Mod Pathol.2012.25(5):699-708.
  7. Mutter GL, Lin MC, Fitzgerald JT, Kum JB,Baak JPA,Lees JA et al.Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers.J Natl Cancer Inst.2000;92(11):924-30.
  8. Nikaido T, Li SF, Shiozawa T, Fujii S. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 1996;78:1248-53.
  9. Quddus MR, Latkovich P, Castellani WJ, Sung CJ, Steinhoff MM, Briggs RC et al. Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis. Arch Pathol Lab Med 2002;126:459-63.
  10. Chaudhary M, Bansal S. Expression of Cyclin D1 in endometrial hyperplasia and carcinoma. Ind J Pathol Microbiol 2007; 50:708-10.
  11. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J et al. The influence of the Cyclin D1 870 G>A polymorphism as an endometrial cancer risk factor. BMC Cancer 2008;8:272.
  12. Abdel-Aziz AF, El-Refaeey AA, Elsaeid AM, Refaat M. Cyclin D1 G870A Polymorphism is associated with an increased risk of simple endometrial hyperplasia in Egyptian women. Biochem Physiol 2014;3:123.
  13. Erkanli S, Kayaselcuk F, Kuscu E, Bagis T, Bolat F, Haberal A et al. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer.2006;16:1412?18.
  14. Rao AC, Arya G, Padma PJ. Immunohistochemical phospho tensin tumor suppressor gene staining patterns in endometrial hyperplasias: a 2-year study. Indian J Pathol Microbiol.2011;54(2):264-8.
  15. Sarmadi S, Mood NI, Sotoudeh, Tavangar S M. Altered PTEN expression; a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium. Diagn Pathol. 2009; 4: 41.
  16. Lee H, Choi HJ, Kang CS, Lee HJ, Lee WS, Park CS. Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma. Modern Pathology.2012; 25:1508-15.
  17. Sheikh S A, Elyasergy D F. Immunoreactivity of PTEN in Cyclic Endometrium and Endometrial Hyperplasia. World Journal of Medical Sciences.2016;13(2):126-32.
  18. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S. Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma. J Med Assoc Thai. 2008;91(8):1161-5.
  19. Orbo A, Nilsen MN, Arnes MS, Pettersen I, Larsen K. Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia. Int J Gynecol Pathol. 2003;22(2):141-8.
  20. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer. 2003;10(2):203-8.
  21. Bueno GM, Perales SR, Estevez CS, Marcos R, Hardisson D, Cigudosa JC et al. Molecular alterations associated with cyclin D1 overexpression in endometrial cancer. Int J Cancer 2003;110:194-200.

[Ekta Rani, Showkat Ahmad Mir, Shuaeb Bhat, Shamim Shera and Shaffy Thukral (2019); STUDY OF EXPRESSION OF PTEN IN ENDOMETRIUM AT A TERTIARY CARE CENTRE Int. J. of Adv. Res. 7 (Oct). 902-906] (ISSN 2320-5407). www.journalijar.com

Dr. Shamim Shera
Senior Consultant, Department of Health, Government of Jammu & Kashmir, Anantnag, Jammu & Kashmir.

DOI:

Article DOI: 10.21474/IJAR01/9906      
DOI URL: https://dx.doi.org/10.21474/IJAR01/9906

Download Full Paper

Download PDF No. of Downloads: 24 | No. of Views: 79